{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:31:02Z","timestamp":1793313062007,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40265-023-01921-5","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:01:26Z","timestamp":1689033686000},"page":"1131-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Beremagene Geperpavec: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"24","key":"1921_CR1","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1056\/NEJMe2212899","volume":"387","author":"DVPD Schaffer","year":"2022","unstructured":"Schaffer DVPD. The coming of age of topical gene therapy for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2279\u201380.","journal-title":"N Engl J Med"},{"issue":"5","key":"1921_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.18609\/cgti.2022.096","volume":"8","author":"T Parry","year":"2022","unstructured":"Parry T, Krishnan S, Prosdocimo DA. A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines. Cell Gene Ther Insights. 2022;8(5):641\u201351.","journal-title":"Cell Gene Ther Insights"},{"issue":"1","key":"1921_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","volume":"17","author":"JA Feinstein","year":"2022","unstructured":"Feinstein JA, Bruckner AL, Chastek B, et al. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):367.","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"1921_CR4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211\u20139.","journal-title":"N Engl J Med"},{"key":"1921_CR5","unstructured":"Krystal Biotech Inc. VYJUVEK\u2122 (beremagene geperpavec-svdt): US prescribing information. 2023. https:\/\/www.krystallabel.com\/pdf\/vyjuvek-us-pi.pdf. Accessed 2 Jun 2023."},{"key":"1921_CR6","unstructured":"US Food & Drug Administration. FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa [media release]. 19 May 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-topical-gene-therapy-treatment-wounds-patients-dystrophic-epidermolysis-bullosa."},{"issue":"4","key":"1921_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780\u20138.","journal-title":"Nat Med"},{"key":"1921_CR8","unstructured":"Carroll K, Zhang P, Duermeyer MJ, et al. Topical application of beremagene geperpavec, an engineered herpes simplex virus type I-based gene therapy vector expressing type VII collagen, is safe and efficacious in a murine corneal wound model. In: DEBRA International Conference. 2021."},{"issue":"5 Suppl","key":"1921_CR9","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.jid.2023.03.915","volume":"143","author":"I Bagci","year":"2023","unstructured":"Bagci I, Momin N, Agostini B, et al. Long term use of topical beremagene geperpavec (B-VEC) in two patients with dystrophic epidermolysis bullosa [abstract no. 905 plus poster]. J Investig Dermatol. 2023;143(5 Suppl):S155.","journal-title":"J Investig Dermatol"},{"key":"1921_CR10","unstructured":"Sabater AL, Tovar A, Gomez J, et al. Topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with dystrophic epidermolysis bullosa. In: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01921-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T11:23:56Z","timestamp":1689938636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01921-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"11 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}